US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Lifeward Ltd. - Ordinary Shares (NQ:LFWD)

6.000 -0.060 (-0.99%)
Delayed Quote Updated: 3:59 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lifeward Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
Experienced leadership team to build on established commercial platform and accelerate Lifeward’s next phase of growth with continuity of strategy 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial... 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Reports First Quarter 2026 Financial Results
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Successfully Closes on Strategic Partnership with Oramed
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Announces Reverse Share Split
Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Appoints Bob Marshall as Chairman of the Board
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
From Lifeward Ltd.
Via GlobeNewswire
News headline image
UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury. 
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Ltd. Reports Third Quarter 2025 Financial Results
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward to Report Third Quarter Financial Results on November 14, 2025
From Lifeward Ltd.
Via GlobeNewswire
News headline image
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
From Lifeward Ltd.
Via GlobeNewswire
News headline image
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union 
From Lifeward Ltd.
Via GlobeNewswire
< Previous 1 2 3 Next >